|
TGen Affiliate, Van Andel Research Institute, Joins with Spectrum Health and Oncology Group
30 July 2010
Cancer patients in West Michigan will soon have the opportunity to access new drugs being developed to fight their disease due to a partnership being formed in Grand Rapids.
|
|
|
|
Two Multi-Site Collaborative Studies Highlight the Value of 454 Sequencing Systems for Genotyping Applications
30 July 2010
Study used the 454 Genome Sequencer FLX System to perform HIV drug-resistant mutation detection.
|
|
|
|
Genetix CloneSelect Imager Can Replace MTT Assay for Cytotoxicity
29 July 2010
Independent publication demonstrates significant advantages over conventional approach.
|
|
|
|
CMS Approves Clinical Study of Genetic Test to Predict Patient Response to Warfarin
27 July 2010
Study to evaluate gene identification ability to predict patient response and improve safety when dosing this anti-blood clotting drug.
|
|
|
|
Genticel’s Therapeutic Vaccine, ProCervix for HPV Receives Clearance to Start a Phase I Clinical Trial
26 July 2010
Entry into Phase I marks a significant milestone for Genticel, which completed a EUR 13.1 million fund-raising in February 2010.
|
|
|
|
NSF Funds Research Partnership Between Bioo Scientific and Mirna Therapeutics
22 July 2010
The funding will support tumor regression and pharmacokinetic studies on targeted delivery of microRNAs.
|
|
|
|
Oncolytics Biotech® Inc. Receives No Objection Letter from Health Canada to Conduct Phase 3 Trial of REOLYSIN®
22 July 2010
The company plans to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with head and neck cancers.
|
|
|
|
AiCuris Presents Mechanism of Action Investigations of its Anti-HCMV Drug AIC246
22 July 2010
Company announce publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah.
|
|
|
|
Actelion Obtains Option to Acquire Privately-Held Trophos
21 July 2010
Trophos' late-stage Phase III compound in Amyotrophic Lateral Sclerosis to report data in late 2011.
|
|
|
|
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets Pre-Specified Endpoint
21 July 2010
PROGRESS is said to be the first study to present 48-week efficacy results for this combination when used in treatment-naive patients with HIV.
|
|
|
|
After 40 Years, NIH-Supported Researchers Identify Possible new Treatment for Severe Vasculitis
16 July 2010
Early results also suggest that patients with disease relapses respond better to the new treatment regimen.
|
|
|
|
Galapagos and University of Bristol Enter Drug Discovery Collaboration in Chronic Pain
16 July 2010
BioFocus will provide hit-to-lead and lead optimization services for a €3.3 million drug discovery program at the University of Bristol.
|
|
|
|
Molecular Insight Pharmaceuticals' Zemiva Phase 2 Data Published in Journal of the American College of Cardiology
15 July 2010
Researchers confirm that addition of Zemiva to available clinical information contributes to the early diagnosis and evaluation of acute coronary syndrome.
|
|
|
|
New Advanced Plating Module for TAP’s Automated Cell Culture System
15 July 2010
Enables production of consistent, high quality cell plates for transport assays.
|
|
|
|
CTI Signs Long-Term Manufacturing Agreement for Pixantrone with NerPharMa
14 July 2010
CTI plans marketing authorization application filing in Europe this year.
|
|
|
|
Selvita and Orion Pharma Will Collaborate on SEL103 - Alzheimer’s Disease Program
12 July 2010
The collaboration focuses further research and development of Selvita’s SEL103 program, for the symptomatic treatment of Alzheimer’s disease.
|
|
|
|
Randox Provides the Gold Standard in Renal Damage Testing – Cystatin C
12 July 2010
PSTC provides data in support of the use of various renal markers, including Cystatin C, in a preclinical setting.
|
|
|
|
Bitop AG Reports that Ectoin® Reduces Symptoms of Acute Allergic Rhinitis
12 July 2010
Ectoin allergy nasal spray has been shown to significantly reduce symptoms of acute allergic rhinitis in a two-week observational study.
|
|
|
|
CIT Announces Availability of Dried Blood Spot Technique for Bioanalytical Services
09 July 2010
The new service is in line with CIT’s policy of continuous enhancements to the range it offers its customers.
|
|
|
|
Proximagen Enters Into a Collaboration Agreement with the NIH
08 July 2010
Under the terms of the CRADA, NINDS will fully fund and carry out a double-blind, cross-over and placebo-controlled Phase II clinical trial in patients with epilepsy.
|
|
|
|
Cambridge Crystallographic Data Centre and InhibOx Create new Powerhouse in Drug Discovery and Development Services
08 July 2010
New service offers sophisticated technologies for drug discovery with cloud computing and software-as-a-service facilities.
|
|
|
|
MorphoSys Receives Research Grant to Advance Anti-CD38 Cancer Program MOR202
07 July 2010
The Company plans to explore relevant biomarkers for the anti-CD38 approach in collaboration with Munich Technical University.
|
|
|
|
Thermo Fisher Scientific Launches Maybridge Ro3 Diversity Fragment Library
06 July 2010
Diverse set of 1,500 molecules engineered for high-quality fragment screening-based programmes.
|
|
|
|
SymBio Initiates Japan Phase 2 Trial of Bendamustine HCl (SyB L-0501) in Multiple Myeloma
05 July 2010
Patients in this multicenter open-label trial will receive the drug in combination with prednisolone.
|
|
|
|
Drug Resistance Danger for Sleeping Sickness Treatments
05 July 2010
Drugs used to treat sleeping sickness must be used prudently to prevent the parasite acquiring resistance to current medicines, research shows.
|
|
|
|
Adverse Cardiovascular Events Reported in Testosterone Trial in Older Men
05 July 2010
The treatment phase of the trial has been stopped due to heart attacks and elevated blood pressure.
|
|
|